Dr. Arthur Mikaelian · Scientist, inventor, founder
The pursuit of a more potent molecule.
For two decades Dr. Arthur Mikaelian has followed a single question across three disciplines: how to make an active compound do more, at a smaller dose. A blue scorpion from Hispaniola, a patented polarization process and a programmable ribosome are his answers so far.
In brief
Los Angeles, California
An independent researcher who carried the language of quantum physics into pharmacology, Dr. Mikaelian works where a natural compound, a physical process and the cell's own machinery meet.
2012
U.S. Patent 8,097,284 B2, polarized scorpion venom solution
176
molecular-mass fractions identified in the venom of H. princeps
12 acres
scorpion reservation in the Dominican Republic
18+ years
of peptide and molecular-delivery research
Chapter 01 · The Blue Scorpion
A venom from the dry forests of Hispaniola.
In 2008 Dr. Mikaelian led a field expedition into the Dominican Republic in search of Heteroctenus princeps, a Caribbean blue scorpion found only in a small area of the island. Its venom carries peptides that act on four families of ion channels.
In 2017 the Dominican Ministry of Environment granted his company access to the species as a genetic resource. The scorpions now live on a protected reservation, where the venom is collected by hand and the animals return to their habitat.
2008
First expedition
2017
Ministry agreement
4
Ion-channel families
Interactive plate · bring the cursor close to the tail
Fig. 2 · The recirculating magnetic loop described in U.S. Patent 8,097,284 B2
Chapter 02 · Polarization
A patent for a more potent solution.
Filed in 2008 and granted in January 2012, U.S. Patent 8,097,284 B2 describes how to polarize a diluted venom solution: the liquid is pumped again and again through tubing pressed between magnets whose like poles face each other.
The same principle later became Mikaelian Resonance Technology, an electromagnetic chamber designed to raise the potency of an active ingredient without raising its dose.
2007
Priority date
2012
Patent granted
MRT-06
Resonance chamber
Chapter 03 · Ribodex
Programming the cell's protein factory.
Every protein in the body is assembled by ribosomes, reading instructions one codon at a time. Ribodex, founded by Dr. Mikaelian in 2023, develops a ribosomal programming platform: a way to give that factory a custom production plan.
Its first application is RiboHair, a needle-free cosmetic hair application delivered in clinics, salons and med spas.
2023
Ribodex LLC founded
2024
Patent application published
RiboHair
First application
Fig. 3 · One ribosome, native and programmed. Schematic.
Dr. Arthur Mikaelian · Los Angeles
Biography
From neuropsychology to quantum biology.
Dr. Arthur Mikaelian is a scientist, inventor and entrepreneur working where biotechnology meets quantum biology. Trained in Moscow in medicine and neuropsychology, he began by studying how stress hormones shape disease, a thread that still runs through his work on ATF3, a stress-responsive gene involved in cancer progression and immune modulation.
He later earned an MBA from the University of Bologna. He has established collaborative programs with NASA on bio-nutrient research for astronaut health and off-Earth agriculture, and received a Certificate of Recognition from the California State Senate for advancing medical innovation.
1980s
Moscow
Studies at the 2nd Medical Institute of Moscow, then earns a PhD in Biological and Neuropsychology at the Vernadsky University of Biosphere Knowledge, followed by post-doctoral research on cortisol, epinephrine and the stress response.
1990s
Los Angeles
Leads a Los Angeles clinic focused on how psychosomatic illness is diagnosed and treated.
2007
Medolife
Founds Medolife and files the first application on the polarization of scorpion venom.
2008
Dominican Republic
Leads the field expedition in search of Heteroctenus princeps.
2012
U.S. Patent 8,097,284 B2
Granted on January 17 for a polarized scorpion venom solution and the method for making it.
2017
Ministry of Environment, Dominican Republic
Research, breeding and access agreements for the species in Neyba, Bahoruco province.
2020
Drug Design, Development and Therapy
Corresponding author of a peer-reviewed review on the venom peptides of Rhopalurus princeps, with co-authors from Johns Hopkins University School of Medicine.
2023
Ribodex
Founds Ribodex LLC and serves as its Chief Scientific Officer.
Today
BioAlliance Holdings
Chief Scientific Officer across Peptigenix, Ribodex, Mikaelian Resonance Technology and an AI preventive-health division.
Neyba, Dominican Republic · still from ABC News Nightline
The expedition · ABC News Nightline
The search for the blue scorpion, on camera.
ABC News Nightline joined Dr. Mikaelian on the expedition to find Heteroctenus princeps in the dry forest of the Dominican Republic, sector by sector, and followed the first specimens into the laboratory.
Record
Patents and papers.
Primary documents behind the three chapters. Every entry links to the public record.
US 8,097,284 B2
Polarized scorpion venom solution and a method for making polarized scorpion venom solution
Granted 2012 ↗
US 2009/0123558 A1
Original publication of the polarization application, filed November 13, 2008
Published 2009 ↗
Drug Des Devel Ther 14:881-893
Pleiotropic anticancer properties of scorpion venom peptides: Rhopalurus princeps venom as an anticancer agent. Review, Mikaelian A.G. et al.
2020 ↗
US 2024/0093187 A1
System and method for tissue rejuvenation and protein synthesis by programmed ribosomes. Application 18/467,595
Published 2024 ↗
U.S. Application 63/828,702
Method for atomic and subatomic particle excitation using resonance frequencies
Pending
Contact
Research partnerships, licensing and speaking.
For scientific collaborations, licensing of the polarization and ribosome platforms, or an invitation to speak.
Los Angeles · California
A venom, a field and a ribosome. Three chapters of one question: how to make a molecule do more, at a smaller dose.
Get in touch
Arthur
Mikaelian
© 2026 Arthur Mikaelian. All rights reserved.
This site describes research, patents and company-reported results. It is not medical advice, and product statements have not been evaluated by the FDA.